Clinical trial Recruiting at 1 site Observational Ages 18 to 90

Automated AI reading of echocardiograms to detect coronary artery disease

Official title: Automated Echocardiographic Detection of Coronary Artery Disease Using Artificial Intelligence Methods

Run by Beijing Hospital · NCT06314295 · Data updated 2026-11-12

This project will test whether artificial intelligence can read heart ultrasound videos to detect coronary artery disease in people who are planning to have coronary angiography.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
Ages18 Years to 90 Years
SexAll
Enrollment1500 (estimated)
SponsorBeijing Hospital
Government
Locations1 site (Beijing)
StatusRecruiting
StartedMarch 11, 2024
Main results expectedMarch 11, 2026
Study endsMay 11, 2026
Registry record updatedNovember 21, 2025
Trial IDNCT06314295 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with suspected coronary artery disease who are planning to undergo coronary angiography and can obtain good-quality transthoracic echocardiogram images.

Probably not a fit

Patients with poor-quality ultrasound images or excluded conditions such as aortic stenosis, prior aortic valve replacement, hypertrophic cardiomyopathy, severe valve disease, severe arrhythmia, severe cardiomyopathy, or severe congenital heart disease are unlikely to benefit from the AI model.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The project uses new ultrasound measures such as non-invasive myocardial work combined with automated image analysis to improve non-invasive detection of coronary artery disease. Researchers will train and apply deep-learning models to classify cardiac ultrasound views, perform automatic segmentation of the left ventricular cavity, myocardium, and left atrial wall using a CLAS model, and track motion to generate velocity vector maps of intracardiac flow. The automated diagnostic model will be validated and optimized by comparing AI outputs with coronary angiography results in patients with suspected coronary artery disease. The work is observational and focuses on cases with adequate image quality while excluding patients with major valvular disease, hypertrophic cardiomyopathy, or severe arrhythmias.

Why it matters

Potential benefit: If successful, this could provide a faster, non-invasive ultrasound-based way to screen and triage people for coronary artery disease, reducing dependence on invasive testing for some patients.

How similar studies have gone: Prior work applying AI to echocardiographic segmentation and automated measurements has shown promising results, but fully automated ultrasound-video diagnostic models for coronary artery disease remain early and not widely validated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with suspected coronary artery disease
* Patients plan to undergo coronary angiography

Exclusion Criteria:

* Patients with aortic valve stenosis
* Patients with aortic valve replacement surgery
* Patients with hypertrophic cardiomyopathy
* Patients with severe heart valve disease
* Patients with severe arrhythmia
* Patients with severe cardiomyopathy
* Patients with severe congenital heart disease
* The quality of ultrasound images is poor

Where it's running

  • Beijing Hospital
    Beijing, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.